Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50934 |
Name | ovarian clear cell carcinoma |
Definition | An ovarian carcinoma that has_material_basis_in cells with clear cytoplasm and glycogen secreting hob nail cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma ovarian clear cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA E545K | Apitolisib | ovarian clear cell carcinoma | predicted - sensitive | detail... |
TP53 del | thioureidobutyronitrile | ovarian clear cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02364713 | Phase II | Pegylated liposomal doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02446600 | Phase III | Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 2 |
NCT02759588 | Phase Ib/II | GL-ONC1 | GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Unknown status | CAN | 0 |
NCT02889900 | Phase II | Cediranib + Olaparib | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) | Completed | USA | 0 |
NCT02900651 | Phase Ib/II | MAK683 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Terminated | USA | ITA | FRA | ESP | DEU | CAN | 4 |
NCT03134638 | Phase I | Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Terminated | USA | FRA | CAN | 0 |
NCT03348631 | Phase II | Tazemetostat | Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT03355976 | Phase II | Ipilimumab + Nivolumab Nivolumab | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | Active, not recruiting | USA | 0 |
NCT03602586 | Phase II | Epacadostat + Pembrolizumab | Pembrolizumab and Epacadostat in Treating Participants With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma | Completed | USA | 1 |
NCT03737643 | Phase III | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + Durvalumab | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O) | Active, not recruiting | USA | TUR | ROU | POL | ITA | HUN | FRA | FIN | ESP | DNK | DEU | CAN | BRA | BGR | BEL | AUT | 4 |
NCT03840200 | Phase Ib/II | Ipatasertib + Rucaparib | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | Completed | USA | ITA | ESP | AUS | 1 |
NCT03955471 | Phase II | Dostarlimab-gxly + Niraparib | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE) | Terminated | USA | 0 |
NCT04034927 | Phase II | Olaparib Olaparib + Tremelimumab | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT04196257 | Phase I | BP1001-A BP1001-A + Paclitaxel | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Unknown status | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04227522 | Phase III | Rucaparib | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (MAMOC) | Active, not recruiting | DEU | 0 |
NCT04374630 | Phase II | Afuresertib + Paclitaxel Paclitaxel | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II) | Completed | USA | 1 |
NCT04611139 | Phase I | Pembrolizumab + Seclidemstat | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Withdrawn | USA | 0 |
NCT04931342 | Phase II | Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | Active, not recruiting | USA | TUR | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS | 2 |
NCT04969887 | Phase II | Ipilimumab + Nivolumab | Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) | Active, not recruiting | NZL | AUS | 0 |
NCT05032040 | Phase II | XmAb20717 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Recruiting | USA | 0 |
NCT05039801 | Phase I | Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05216432 | Phase I | RLY-2608 Fulvestrant + RLY-2608 | First-in-Human Study of Mutant-selective PI3Kalpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | Recruiting | USA | ITA | FRA | ESP | AUS | 0 |
NCT05296512 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer | Recruiting | USA | 0 |
NCT05300048 | Phase I | Serabelisib Nab-paclitaxel + Serabelisib | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | Active, not recruiting | USA | 0 |
NCT05397093 | Phase I | ITIL-306 | ITIL-306 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05415098 | Phase I | APG-5918 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05498597 | Phase I | AMT-151 | AMT-151 in Patients With Selected Advanced Solid Tumours | Recruiting | AUS | 1 |
NCT05715216 | Phase II | Etigilimab + Nivolumab | EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | Recruiting | USA | 0 |
NCT05920798 | Phase Ib/II | FR alpha peptide vaccine + Pembrolizumab | A Study of FRaDCs for Ovarian Cancer | Recruiting | USA | 0 |
NCT05950464 | Phase I | M1774 + ZEN-3694 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | Recruiting | USA | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06065462 | Phase Ib/II | Dostarlimab-gxly + LB-100 | Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 | Recruiting | USA | 0 |
NCT06457997 | Phase I | PHN-010 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06646627 | Phase I | B7-H3 CAR T cells | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | Not yet recruiting | USA | 0 |
NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Not yet recruiting | USA | 0 |
NCT06677190 | Phase II | Belzutifan | Belzutifan in Recurrent Clear Cell Ovarian Carcinoma | Not yet recruiting | USA | 0 |